Thompson K, Job C K
Purulia Leprosy Home and Hospital, West Bengal, India.
Int J Lepr Other Mycobact Dis. 1996 Sep;64(3):306-10.
Iridectomy specimens from 59 leprosy patients who had adequate medical records of whom 33 belong to the lepromatous (LL) leprosy variety and 16 normal controls were studied histopathologically. All patients were bacteriologically negative and had received dapsone followed by multidrug therapy (MDT), or MDT only, or only dapsone for varying periods. It was found that leprosy, particularly lepromatous disease, did not significantly decrease the age of formation of cataract. Of the 33 LL patients studied 60.6% had silent iritis. The duration of treatment had no obvious influence on the persistence of iritis. Treatment with only 2 years of MDT for LL patients did not significantly increase the prevalence of persistent silent iritis compared to those who received other types of antileprosy therapy for long periods. It is pointed out that chronic iritis is a serious complication that continues even after the patient is declared clinically and bacteriologically cured, especially in patients who had a history of chronic iritis clinically.
对59例有完整病历的麻风患者的虹膜切除术标本进行了组织病理学研究,其中33例属于瘤型(LL)麻风,另有16例作为正常对照。所有患者细菌学检查均为阴性,且接受过不同疗程的氨苯砜治疗,随后接受了多药联合治疗(MDT),或仅接受MDT,或仅接受氨苯砜治疗。研究发现,麻风,尤其是瘤型麻风,并未显著降低白内障形成的年龄。在研究的33例LL患者中,60.6%患有隐匿性虹膜炎。治疗时间对虹膜炎的持续存在没有明显影响。与长期接受其他类型抗麻风治疗的患者相比,LL患者仅接受2年MDT治疗并未显著增加持续性隐匿性虹膜炎的患病率。需要指出的是,慢性虹膜炎是一种严重的并发症,即使在患者临床和细菌学检查均宣告治愈后仍会持续存在,尤其是那些临床上有慢性虹膜炎病史的患者。